Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Carisma Therapeutics Inc CARM

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

NDAQ:CARM - Post Discussion

Carisma Therapeutics Inc > 4 BIOTECH STOCKS FACING FDA REJECTION!
View:
Post by AviseAnalytics on Aug 24, 2021 7:36am

4 BIOTECH STOCKS FACING FDA REJECTION!

4 BIOTECH STOCKS FACING FDA REJECTION!

 

Is it a full stop or a pause to their journey?

 

SESN FGEN SPPI ARDX

Read More:

https://www.aviseanalytics.com/4-biotech-stocks-facing-fda-rejection/
[url=https://www.aviseanalytics.com/4-biotech-stocks-facing-fda-rejection/
]Click Here[/url]

Comment by floatinketucky on Jan 24, 2022 6:51am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities